Unlike alcohol and nicotine, there is no FDA-approved pharmacological treatment for cocaine use disorder (CoCUD). The purpose of this study was to investigate clavulanic acid (CLAV), a GLT-1 activator, for its potential to treat CoCUD. Resting state fMRI was used to assess changes in the anterior cingulate cortex (ACC) functional connectivity with repeated CLAV for 10 days. CLAV altered the connectivity of ACC with default mode network, motor control, and addiction cue reactivity related regions. This pilot study supports the development of CLAV for CoCUD treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords